The rapid development of China's RAS-targeted cancer drugs could reshape global oncology and unlock the country's undervalued ...

By Deena Beasley SAN DIEGO, June 22 (Reuters) - China, which now conducts more clinical drug trials than the U.S., still lags in the quality and commercial reach of its biomedical science, according ...

Chinese drugmaker Innovent Biologics could receive up to $11.4 billion from a cancer-drug partnership with Japan’s Takeda Pharmaceutical, marking the latest in a wave of tie-ups between Chinese ...

Already, they’re laying the groundwork for additional legislative and regulatory measures to counter the rise of Chinese ...

Add Yahoo as a preferred source to see more of our stories on Google. When you or your child next take a dose of antibiotics, consider that 90 percent of its raw ingredients were likely manufactured ...

House committee launches investigation into Eli Lilly's China clinical trials at military hospitals and Xinjiang facilities, ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in ...

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...

The Trump administration is considering putting “severe restrictions” on the increasing flow of investigational drugs from China, according to reporting by The New York Times. A draft executive order ...

Forbes contributors publish independent expert analyses and insights. Anjalee Khemlani is an award-winning business and health journalist. This voice experience is generated by AI. Learn more. This ...